What is Erste Group Bank's Forecast for TMO FY2027 Earnings?

Key Points

• Erste Group Bank raised its FY2027 EPS forecast for Thermo Fisher Scientific to $27.58 from $27.51, above the current full-year consensus estimate of $25.16.
• Thermo Fisher exceeded quarterly expectations, reporting $6.68 EPS versus $6.40 expected and revenue of $12.14 billion, up 9.1% year over year.
• Analyst sentiment remains favorable, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $675.52, although recent insider selling and elevated valuation present potential risks.

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Equities research analysts at Erste Group Bank boosted their FY2027 earnings per share estimates for shares of Thermo Fisher Scientific in a report released on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the medical research company will earn $27.58 per share for the year, up from their previous estimate of $27.51. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $25.16 per share.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, beating analysts' consensus estimates of $6.40 by $0.28. The business had revenue of $12.14 billion during the quarter, compared to analysts' expectations of $11.95 billion. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The business's revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business earned $5.79 earnings per share.

Other analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $720.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Scotiabank initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an "outperform" rating for the company. Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c+)" rating to a "buy (b-)" rating in a report on Thursday, October 8th. Barclays lifted their target price on shares of Thermo Fisher Scientific from $750.00 to $775.00 and gave the stock an "overweight" rating in a research note on Thursday. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average target price of $675.52.

Thermo Fisher Scientific Stock Down 2.6%

TMO opened at $676.09 on Friday. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $705.78. The company has a quick ratio of 1.18, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The company has a 50-day moving average price of $644.01 and a 200 day moving average price of $553.96. The company has a market cap of $249.98 billion, a PE ratio of 36.37, a price-to-earnings-growth ratio of 2.89 and a beta of 0.87.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer owned 24,651 shares in the company, valued at $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. Corporate insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently made changes to their positions in TMO. Strengthening Families & Communities LLC lifted its stake in shares of Thermo Fisher Scientific by 0.4% in the 3rd quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company's stock valued at $3,187,000 after purchasing an additional 21 shares during the last quarter. Bell Bank increased its position in shares of Thermo Fisher Scientific by 10.8% during the 3rd quarter. Bell Bank now owns 624 shares of the medical research company's stock worth $421,000 after purchasing an additional 61 shares during the last quarter. 55 North Private Wealth LLC raised its holdings in Thermo Fisher Scientific by 40.9% in the 3rd quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company's stock valued at $612,000 after buying an additional 263 shares during the period. Jeppson Wealth Management LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $213,000. Finally, James Hambro & Partners LLP lifted its position in Thermo Fisher Scientific by 0.8% in the third quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company's stock valued at $156,260,000 after buying an additional 1,919 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 beat and stronger outlook: Thermo Fisher reported third-quarter revenue of $12.14 billion, up 9.1% year over year, while adjusted EPS of $6.68 exceeded the $6.40 consensus estimate. Organic growth reached 6%, margins improved, and management raised its full-year 2026 revenue-growth and earnings outlook. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Analysts remain bullish: TD Cowen raised its price target to $810 and retained a “buy” rating. Stifel Nicolaus lifted its target to $775, while Robert W. Baird raised its target to $756 and maintained an “outperform” rating. The revisions reflect confidence in recovery across clinical research, bioproduction and laboratory products.
• Positive Sentiment: Industry growth supports long-term demand: Research indicates the peptide-synthesis market could expand from $0.98 billion in 2026 to $1.54 billion by 2031, aided by GLP-1 drug development. Thermo Fisher is among the companies positioned to benefit from increased pharmaceutical and research activity. Global Peptide Synthesis Market Forecast
• Neutral Sentiment: Peer comparison: A new survey compares Thermo Fisher with Twist Bioscience, but it does not provide a clear new company-specific catalyst for TMO. Twist Bioscience versus Thermo Fisher Scientific
• Negative Sentiment: Options activity signals caution: Heavy put-option buying, including activity roughly 52% above average, suggests some traders are hedging against a pullback or positioning defensively after the earnings release. Thermo Fisher Scientific Stock Sees Heavy Put Option Buying
• Negative Sentiment: Muted earnings reaction and valuation risk: The strong report has not produced a sustained rally, potentially because TMO trades near its 12-month high at a forward-looking premium valuation. Investors may be demanding clearer evidence that the end-market recovery can justify the stock’s elevated earnings multiple.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.